Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIO-301 in Late-stage Retinitis Pigmentosa
NCT06628947Phase 2Recruiting
- Sponsor
- Kiora Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KIO-301 in retinitis pigmentosa (RP) (2 arms), sponsored by Kiora Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple doses of KIO-301. Started Aug 2025; status: recruiting.
02
Drugs
KIO-301
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06628947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628947.